| Cost-effectiveness analysis of lung cancer screening in the United States: a comparative modeling study SD Criss, P Cao, M Bastani, K Ten Haaf, Y Chen, DF Sheehan, EF Blom, ... Annals of internal medicine 171 (11), 796-804, 2019 | 109 | 2019 |
| Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare DF Sheehan, SD Criss, Y Chen, A Eckel, L Palazzo, AC Tramontano, ... Cancer medicine 8 (1), 94-103, 2019 | 79 | 2019 |
| Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non–small cell lung cancer in the United States SD Criss, MJ Mooradian, TR Watson, JF Gainor, KL Reynolds, CY Kong JAMA network open 2 (9), e1911952-e1911952, 2019 | 63 | 2019 |
| Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung … SD Criss, MJ Mooradian, DF Sheehan, L Zubiri, MA Lumish, JF Gainor, ... JAMA oncology 5 (3), 358-365, 2019 | 60 | 2019 |
| Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/μl CY Kong, K Sigel, SD Criss, DF Sheehan, M Triplette, MJ Silverberg, ... Aids 32 (10), 1333-1342, 2018 | 41 | 2018 |
| Cost and utilization of lung cancer end‐of‐life care among racial‐ethnic minority groups in the United States Y Chen, SD Criss, TR Watson, A Eckel, L Palazzo, AC Tramontano, ... The oncologist 25 (1), e120-e129, 2020 | 27 | 2020 |
| Population impact of lung cancer screening in the United States: projections from a microsimulation model SD Criss, DF Sheehan, L Palazzo, CY Kong PLoS Medicine 15 (2), e1002506, 2018 | 23 | 2018 |
| Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach DF Sheehan, SD Criss, GS Gazelle, PV Pandharipande, CY Kong PLoS One 12 (3), e0173119, 2017 | 17 | 2017 |
| Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States SD Criss, DT Weaver, DF Sheehan, RJ Lee, PV Pandharipande, CY Kong Urologic Oncology: Seminars and Original Investigations 37 (3), 180. e11-180 …, 2019 | 16 | 2019 |
| Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden SD Criss, L Palazzo, TR Watson, AM Paquette, K Sigel, J Wisnivesky, ... PLoS One 15 (1), e0228288, 2020 | 12 | 2020 |
| A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea Y Chen, TR Watson, SD Criss, A Eckel, L Palazzo, DF Sheehan, CY Kong Plos one 14 (7), e0220610, 2019 | 5 | 2019 |
| Acceptability and utility of a virtual pediatric transplant peer mentoring program: A mixed‐methods analysis of a novel quality improvement program SD Criss, LA Dageforde, TM Coe, RA Brandes, S Li, E Keegan‐Pitts, ... Pediatric Transplantation 26 (7), e14345, 2022 | 2 | 2022 |
| Cost-effectiveness analysis of lung cancer screening in the United States SD Criss, HJ de Koning, SK Plevritis, R Meza, CY Kong Annals of Internal Medicine 172 (10), 706-707, 2020 | 2 | 2020 |
| Changes to model assumptions of the cost-effectiveness of durvalumab therapy for non-small cell lung cancer—in reply SD Criss, MJ Mooradian, CY Kong JAMA oncology 5 (7), 1066-1067, 2019 | 1 | 2019 |
| A simulation study of the effect of screening on lung cancer mortality in Asia Y Chen, SD Criss, DF Sheehan, CY Kong Value in health 21, S23, 2018 | 1 | 2018 |
| Preferred language and disease severity predict evaluation for liver transplantation among patients admitted with alcohol-associated hepatitis DJ Cloonan, JM Broekhuis, TM Coe, S Criss, S Li, SJ Bartels, H Yeh, ... European journal of gastroenterology & hepatology 35 (8), 907-913, 2023 | | 2023 |
| Y Factors Associated with Referral to a Transplant Specialist among Patients Admitted with Acute Alcoholic Hepatitis D Cloonan, J Broekhuis, T Coe, S Criss, S Li, M Karam, A Shah, ... AMERICAN JOURNAL OF TRANSPLANTATION 22, 63-64, 2022 | | 2022 |
| Cost-Effectiveness Analysis of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States S Criss, M Mooradian, T Watson, J Gainor, K Reynolds, CY Kong 41st Annual Meeting of the Society for Medical Decision Making, 2019 | | 2019 |
| A simulation study of the effect of lung cancer screening in China, Japan, Singapore, and South Korea. CYF Chen YuFan, TR Watson, SD Criss, A Eckel, L Palazzo, DF Sheehan, ... | | 2019 |
| Effect of Comorbidities on the Cost-Effectiveness of Immunotherapies for Advanced Non-Small Cell Lung Cancer S Criss, X Chen, D Sheehan, CY Kong 40th Annual Meeting of the Society for Medical Decision Making, 2018 | | 2018 |
